Licensing
Vaccines developed by Intravacc
Advancing vaccines through licensing
Our vaccine developments are available for continued development and commercialization via licensing. Licensees are granted permission to use our vaccine technology, intellectual property, and/or manufacturing process under a tailored contractual agreement.
Additionally, our vaccine production platforms can be licensed. The underlying technologies are Intravacc intellectual property protected by a strong patent portfolio. Discover our proprietary platforms…
Licensing offers several advantages:
- Accelerated Development: working together on vaccine development, we speed up the process.
- Cost Sharing: sharing the financial burden of research and development makes vaccine development more financially viable.
- Leveraging Expertise: merging the expertise of different organizations fosters innovation and increases the chances of success.
- Wider Access: multiple licensees can manufacture and distribute a vaccine, increasing its availability, especially in underserved regions.
- Global Impact: licensing promotes international cooperation, facilitating the production of vaccines that address global health challenges.
- Risk Mitigation: licensing spreads the risk of vaccine development among various parties.
- Technology Transfer: knowledge sharing and technology transfer can benefit local manufacturing capacity and scientific expertise.
Intellectual property excellence and knowledge sharing strategy:
At Intravacc, our expertise in vaccine composition and production processes is unparalleled, and we continually expand our knowledge in this highly competitive field. To safeguard our innovations and maintain our technological edge, we employ three distinct strategies:
-
Findings publication
We share our research findings through publications, attracting potential partners in collaborations that acknowledge our expertise. -
Trade secrets
Certain technologies, like our proprietary N. meningitis medium, are kept confidential as valuable trade secrets. Some in-house knowledge is difficult to patent but constitute commercially sensitive information that is important to safeguard. -
Patent protection
We file for patents to secure a 20-year monopoly on ground-breaking technologies. This approach is a gold standard, ensuring freedom to operate and a significant commercial advantage. Our patent portfolio encompasses EU filings plus a global strategy tailored to major markets such as the USA, Canada, India, Japan, China, and Brazil. We focus on protecting our knowledge where it matters most.
Strenght through partnerships
Intravacc collaborates with a diverse network of global partners, including universities, government institutions, biotech, and pharmaceutical companies. Our mission is to advance promising vaccine candidates through the development pipeline. We specialize in innovative vaccine concepts and provide tailored solutions to meet unique needs.
Partners in vaccine concept development
Our state-of-the-art facilities are equipped to work with various vaccine platforms, allowing us to produce customized GMP-grade pilot lots that support your phase I or II clinical trials. We are currently engaged in active partnerships with biotech and government organizations, via various collaboration models, including licensing agreements.
Publicly funded partnerships
In conjunction with our partners, we actively participate in obtaining public funding for the development of novel vaccine concepts and clinical studies. Several projects are currently underway.
Explore partnership opportunities
Intravacc offers non-exclusive partnership opportunities for several proprietary technologies, including:
- Outer Membrane Vesicle-based vaccine technology
- Cell-Based vaccine technology
- Conjugation-based vaccine technology
- Escherichia coli expression system technology